Health Trials

SARS CoV-2 Post-Acute Sequelae

2

Review clinical trials related to SARS CoV-2 Post-Acute Sequelae. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.

Participants needed: 60
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: University of Alabama at BirminghamUpdated: Jun 2, 2026Locations: 1
Eligibility criteria

18 to 65 years of age [+4]

Contraindication to MRI [+9]

Read more
Status: Recruiting

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.

Participants needed: 118
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Mount Sinai Hospital, CanadaUpdated: Jan 24, 2025Locations: 4
Eligibility criteria

≥18 years old [+3]

Absolute contraindications to Paxlovid or Veklury (any of the following): Severe... [+5]

Read more